Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Drugs & Therapy Perspectives
Erschienen in: Drugs & Therapy Perspectives 8/2023

21.07.2023 | Practical Issues and Updates

Screen for drug-induced gambling disorder in vulnerable patients receiving dopaminergic drugs

verfasst von: Simon Fung

Erschienen in: Drugs & Therapy Perspectives | Ausgabe 8/2023

Einloggen, um Zugang zu erhalten

Abstract

Dopaminergic drugs are associated with an increased risk of gambling disorder. It is crucial that patients who are at risk of- or who have developed a gambling disorder are identified so that preventative interventions and treatment can be provided as patients with gambling disorder do not typically seek help. Modification to the dose or the type of dopaminergic drugs prescribed is recommended in cases of drug-induced gambling disorder alongside standard psychological interventions.
Literatur
1.
Wolfschlag M, Hakansson A. Drug-induced gambling disorder: epidemiology, neurobiology, and management. Pharm Med. 2023;37(1):37–52.CrossRef
2.
Clark L, Boileau I, Zack M. Neuroimaging of reward mechanisms in gambling disorder: an integrative review. Mol Psychiatry. 2019;24(5):674–93.CrossRefPubMed
3.
4.
5.
Grall-Bronnec M, Sauvaget A, Perrouin F, et al. Pathological gambling associated with aripiprazole or dopamine replacement therapy: do patients share the same features? A review. J Clin Psychopharmacol. 2016;36(1):63–70.CrossRefPubMed
6.
Ambermoon P, Carter A, Hall WD, et al. Impulse control disorders in patients with Parkinson’s disease receiving dopamine replacement therapy: evidence and implications for the addictions field. Addiction. 2011;106(2):283–93.CrossRefPubMed
7.
Gallagher DA, O’Sullivan SS, Evans AH, et al. Pathological gambling in Parkinson’s disease: risk factors and differences from dopamine dysregulation. An analysis of published case series. Mov Disord. 2007;22(12):1757–63.CrossRefPubMed
8.
Potenza MN, Walderhaug E, Henry S, et al. Serotonin 1B receptor imaging in pathological gambling. World J Biol Psychiatry. 2013;14(2):139–45.CrossRefPubMed
9.
Cornelius JR, Tippmann-Peikert M, Slocumb NL, et al. Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case–control study. Sleep. 2010;33(1):81–7.PubMedPubMedCentral
10.
Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67(5):589–95.CrossRefPubMed
11.
Zack M, Poulos CX. A D2 antagonist enhances the rewarding and priming effects of a gambling episode in pathological gamblers. Neuropsychopharmacology. 2007;32(8):1678–86.CrossRefPubMed
12.
Tremblay AM, Desmond RC, Poulos CX, et al. Haloperidol modifies instrumental aspects of slot machine gambling in pathological gamblers and healthy controls. Addict Biol. 2011;16(3):467–84.CrossRefPubMed
13.
Menon R, Cribb L, Sarris J, et al. A case of acute problem gambling associated with agomelatine. J Clin Psychopharmacol. 2018;38(2):153–5.CrossRefPubMed
14.
Sakurada K, Nibuya M, Yamada K, et al. Kleptomania induced by venlafaxine. Case Rep Psychiatry. 2021;2021:8470045.PubMedPubMedCentral
15.
Egorov AY. The use of agomelatine (valdoxan) in gambling therapy: a pilot study. Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(9):28–31.CrossRefPubMed
16.
Camardese G, Picello A, Bria P. Venlafaxine: successful treatment in impulsive disorders. Psychiatry Clin Neurosci. 2008;62(2):241–2.CrossRefPubMed
17.
Zack M, Poulos CX. Amphetamine primes motivation to gamble and gambling-related semantic networks in problem gamblers. Neuropsychopharmacology. 2004;29(1):195–207.CrossRefPubMed
18.
Smart K, Desmond RC, Poulos CX, et al. Modafinil increases reward salience in a slot machine game in low and high impulsivity pathological gamblers. Neuropharmacology. 2013;73:66–74.CrossRefPubMed
19.
Dowling NA, Merkouris SS, Greenwood CJ, et al. Early risk and protective factors for problem gambling: a systematic review and meta-analysis of longitudinal studies. Clin Psychol Rev. 2017;51:109–24.CrossRefPubMed
20.
Otto JL, Smolenski DJ, Garvey Wilson AL, et al. A systematic review evaluating screening instruments for gambling disorder finds lack of adequate evidence. J Clin Epidemiol. 2020;120:86–93.CrossRefPubMed
21.
Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol. 2010;67(1):58–63.CrossRefPubMed
22.
Mamikonyan E, Siderowf AD, Duda JE, et al. Long-term follow-up of impulse control disorders in Parkinson’s disease. Mov Disord. 2008;23(1):75–80.CrossRefPubMedPubMedCentral
23.
Jiménez-Murcia S, Bove FI, Israel M, et al. Cognitive-behavioral therapy for pathological gambling in Parkinson’s disease: a pilot controlled study. Eur Addict Res. 2012;18(6):265–74.CrossRefPubMed
Metadaten
Titel
Screen for drug-induced gambling disorder in vulnerable patients receiving dopaminergic drugs
verfasst von
Simon Fung
Publikationsdatum
21.07.2023
Verlag
Springer International Publishing
Erschienen in
Drugs & Therapy Perspectives / Ausgabe 8/2023
Print ISSN: 1172-0360
Elektronische ISSN: 1179-1977
DOI
https://doi.org/10.1007/s40267-023-01015-y

Weitere Artikel der Ausgabe 8/2023

Drugs & Therapy Perspectives 8/2023 Zur Ausgabe

Adis Drug Q&A

Desidustat in anaemia in patients with chronic kidney disease: a profile of its use

Adis Drug Q&A

Oteseconazole in recurrent vulvovaginal candidiasis: a profile of its use

Practical Issues and Updates

Manage androgenetic alopecia in men with established options but emerging therapies show promise

Adis Drug Q&A

Dextromethorphan/bupropion in major depressive disorder: a profile of its use

Disease Management

Manage early morning ADHD symptoms and functional impairment with treatments that are effective from awakening